Cymbiotika, a wellness and supplement brand, completed a $30 million debt financing round. The financing was led by RevTek Capital, a capital provider specializing in strategic debt financing.
The partnership with RevTek Capital is aimed at allowing Cymbiotika to strengthen its balance sheet and provide the necessary working capital to support key initiatives, including expansion into retail, entering the Canadian market and enhancing infrastructure and automation.
“The successful completion of this financing round signifies the strength of our brand, the value of our products and our immense potential in the market,” Shahab Elmi, CEO and co-founder of Cymbiotika, said. “RevTek Capital made the entire process incredibly smooth and easy for us. Their team’s deep knowledge and expertise were evident every step of the way, and they provided invaluable guidance in structuring this financing. This partnership allows us to further scale our operations, enter new markets, and drive long-term sustainable growth. We’re excited for the road ahead and our continued mission to empower individuals to take control of their health.”
The financing will also provide Cymbiotika with the resources to optimize its supply chain and scale its digital and omnichannel marketing efforts, ensuring the company is well-positioned to meet both its immediate and long-term growth goals.
“Cymbiotika is a remarkable company that has grown rapidly by staying true to its mission of delivering premium wellness products,” Scott Peters, CEO and founder of RevTek Capital, said. “At RevTek, we are proud to partner with forward-thinking companies like Cymbiotika that are making a meaningful impact on people’s lives. We look forward to supporting their continued success and growth.”
